(UroToday.com) The treatment landscape in advanced prostate cancer has rapidly evolved. In the context of metastatic castration resistant prostate cancer (mCRPC), docetaxel was the first agent to demonstrate a survival benefit when combined with conventional androgen deprivation therapy (ADT). Following this, a number of androgen receptor targeting agents have been assessed, beginning with abiraterone acetate and enzalutamide. Despite their overall tolerable risk profiles, some cardiotoxicity signals were reported for these agents in clinical trials but little is known about their incidence in clinical practice. However, these agents haven’t been directly compared in randomized controlled trials.